Valuation: SI-BONE, Inc.

Market Cap 771M 674M 622M 573M 1.08B 74.23B 1.1B 7.43B 2.92B 36.35B 2.89B 2.83B 125B P/E 2026 *
-40x
P/E 2027 * -47.9x
Enterprise Value 771M 674M 622M 573M 1.08B 74.23B 1.1B 7.43B 2.92B 36.35B 2.89B 2.83B 125B EV / Sales 2026 *
3.33x
EV / Sales 2027 * 2.89x
Free-Float
96.58%
Yield 2026 *
-
Yield 2027 * -
1 day-1.92%
1 week-1.03%
Current month+6.50%
1 month+9.72%
3 months+23.35%
6 months+2.24%
Current year-11.87%
1 week 16.42
Extreme 16.42
18.17
1 month 15.59
Extreme 15.59
18.17
Current year 11.48
Extreme 11.48
21.89
1 year 11.48
Extreme 11.48
21.89
3 years 11.48
Extreme 11.48
26.03
5 years 11.14
Extreme 11.14
31.54
10 years 7.2
Extreme 7.2
37.21
Manager TitleAgeSince
Chief Executive Officer 59 2021-04-19
Director of Finance/CFO 46 2021-04-18
Chief Tech/Sci/R&D Officer 64 2017-01-31
Director TitleAgeSince
Chairman 71 2008-03-17
Director/Board Member 72 2012-12-31
Director/Board Member 56 2008-03-17
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Sell

Chief Financial Officer

-3,317 0.0075%
7/2/26 Sell

General Counsel

-3,134 0.0071%
6/5/26 Sell

Founder

-3,575 0.0081%
Change 5-day change 1-year change 3-year change Capi.($)
-1.92%-1.03%+4.57%-32.24% 771M
-0.40%+0.07%+38.17%+1.20% 12.52B
+10.14%+11.94%+15.79%+20.31% 6.57B
+2.91%-0.11%+55.48%+29.66% 5.83B
+6.61%+10.73% - - 4.75B
-2.77%-0.34%-29.59%+15.87% 4.25B
-2.01%+4.84%-22.35%-22.76% 4.02B
-3.05%-2.33%-0.62%-59.82% 1.84B
-3.31%-6.97%-4.51%+246.89% 1.8B
0.00%+0.66%+59.44%-3.17% 1.56B
Average +0.62%+1.52%+12.93%+21.77% 4.39B
Weighted average by Cap. +1.75%+2.77%+19.83%+15.40%

Financials

2026 *2027 *
Net sales 232M 202M 187M 172M 325M 22.31B 332M 2.23B 878M 10.93B 870M 851M 37.61B 267M 233M 215M 198M 374M 25.68B 382M 2.57B 1.01B 12.58B 1B 979M 43.29B
Net income -19.59M -17.12M -15.8M -14.56M -27.45M -1.89B -28.06M -189M -74.27M -924M -73.58M -71.96M -3.18B -16.77M -14.66M -13.52M -12.47M -23.5M -1.62B -24.02M -162M -63.58M -791M -62.98M -61.6M -2.72B
Net Debt - -
Logo SI-BONE, Inc.
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Employees
376
Date Price Change Volume
26-07-17 US$17.38 -1.92% 403,799
26-07-16 US$17.72 +2.72% 552,895
26-07-15 US$17.25 +2.01% 447,373
26-07-14 US$16.91 -5.27% 638,989
26-07-13 US$17.85 +1.65% 411,159
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
17.38USD
Average target price
24.50USD
Spread / Average Target
+40.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SIBN Stock